PodParley PodParley
PodParley
Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate episode artwork

EPISODE · Feb 18, 2026 · 11 MIN

Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate

from BiotechTV - News · host BiotechTV

CEO Tim Sharpington and CMO Robert Tansley walk us through the treatment, which contains a defined consortium of eight live gut commensal bacterial strains, and the data.

What this episode covers

CEO Tim Sharpington and CMO Robert Tansley walk us through the treatment, which contains a defined consortium of eight live gut commensal bacterial strains, and the data.

NOW PLAYING

Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate

0:00 11:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 11 minutes long.

When was this BiotechTV - News episode published?

This episode was published on February 18, 2026.

What is this episode about?

CEO Tim Sharpington and CMO Robert Tansley walk us through the treatment, which contains a defined consortium of eight live gut commensal bacterial strains, and the data.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!